aflibercept
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy Without Active Polyp
Conditions
Polypoidal Choroidal Vasculopathy Without Active Polyp
Trial Timeline
Feb 1, 2014 → Nov 2, 2017
NCT ID
NCT02072408About aflibercept
aflibercept is a approved stage product being developed by Bayer for Polypoidal Choroidal Vasculopathy Without Active Polyp. The current trial status is completed. This product is registered under clinical trial identifier NCT02072408. Target conditions include Polypoidal Choroidal Vasculopathy Without Active Polyp.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04113538 | Phase 3 | UNKNOWN |
| NCT02633852 | Approved | Completed |
| NCT02661711 | Phase 2 | Completed |
| NCT02072408 | Approved | Completed |
| NCT02157077 | Phase 3 | Completed |
| NCT01950741 | Approved | Completed |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy Without Active Polyp
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 82 |
| aflibercept 8 mg | Bayer | Phase 3 | 74 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 25 |